Giuseppe Luigi Banna
YOU?
Author Swipe
View article: The risk of lung cancer from vaping or e-cigarette usage: a systematic review
The risk of lung cancer from vaping or e-cigarette usage: a systematic review Open
This systematic review suggests a potential association between EC use and an increased risk of lung cancer, particularly among dual users; however, causality cannot be established due to heterogeneity and limited longitudinal data.
View article: Who Truly Benefits From First-Line Intensification in EGFR-Mutant NSCLC?
Who Truly Benefits From First-Line Intensification in EGFR-Mutant NSCLC? Open
Purpose of Review The treatment landscape for advanced non-small cell lung cancer (NSCLC) with common EGFR mutations has evolved significantly, with osimertinib established as the first-line standard. Two recent phase III trials, FLAURA2 a…
View article: Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods
Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods Open
Objectives In non-small cell lung cancer (NSCLC), non-invasive alternatives to biopsy-dependent driver mutation analysis are needed. We reviewed the effectiveness of radiomics alone or with clinical data and assessed the performance of art…
View article: Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry Open
Background With nearly one-third of patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 Tumor Proportion Score≥50% surviving beyond 5 years following first-line pembrolizumab, long-term outcomes challenge traditional paradi…
View article: IUC24417-83 Correlation of circulating tumor DNA with oncological endpoints in metastatic urothelial cancer: a systematic review and meta-analysis of phase II/III clinical trials
IUC24417-83 Correlation of circulating tumor DNA with oncological endpoints in metastatic urothelial cancer: a systematic review and meta-analysis of phase II/III clinical trials Open
Background Metastatic urothelial cancer (mUC) bears a poor prognosis, with current surveillance strategies offering limited precision. Biomarkers such as circulating tumor DNA (ctDNA) are emerging tools to monitor treatment response in ear…
View article: IUC24406-81 ARTA-ATTACK study: assessment of sarcopenia, frailty, and neurocognitive impairment in patients with prostate cancer treated with androgen receptor-targeted agents: a prospective multicenter observational cohort study
IUC24406-81 ARTA-ATTACK study: assessment of sarcopenia, frailty, and neurocognitive impairment in patients with prostate cancer treated with androgen receptor-targeted agents: a prospective multicenter observational cohort study Open
Background Treatment of prostate cancer has evolved significantly over the past decade with the introduction of androgen receptor-targeted agents (ARTAs) such as enzalutamide, abiraterone, apalutamide, and darolutamide. These agents have…
View article: IUC24433-81 Docetaxel versus olaparib plus abiraterone as first-line treatment in patients with mCRPC: a retrospective single-center analysis
IUC24433-81 Docetaxel versus olaparib plus abiraterone as first-line treatment in patients with mCRPC: a retrospective single-center analysis Open
Background Olaparib and abiraterone (Ola+Abi) has emerged as a novel first-line (1L) treatment option for metastatic castration-resistant prostate cancer (mCRPC), but comparisons with docetaxel are lacking. We retrospectively evaluated out…
View article: The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation
The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation Open
Globally, lung cancer remains the most common cause of cancer mortality, with non-small-cell lung cancer (NSCLC) being the most common subtype of lung cancer diagnosed. This review paper provides a comprehensive landscape of clinical predi…
View article: Global variations in oncology professionals’ confidence levels for managing antibody–drug conjugate toxicities: a cross-continental survey
Global variations in oncology professionals’ confidence levels for managing antibody–drug conjugate toxicities: a cross-continental survey Open
Background Antibody–drug conjugates (ADCs) represent a promising therapeutic approach in oncology, but managing their toxicities remains challenging. This survey aimed to assess confidence levels in ADC toxicity management among oncology p…
View article: Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management Open
The discovery of activating mutations in the epidermal growth factor receptor ( EGFR ) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer imp…
View article: Ghrelin-induced neuronal NPY promotes brain metastasis in lung cancer patients with low BMI
Ghrelin-induced neuronal NPY promotes brain metastasis in lung cancer patients with low BMI Open
Obesity is a known risk factor for many cancers, yet recent studies reveal a paradoxical association between low body mass index (BMI) and increased brain metastasis in lung cancer—referred to as the “obesity paradox,” with unclear molecul…
View article: The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab Open
The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent A…
View article: Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone–Sensitive Prostate Cancer
Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone–Sensitive Prostate Cancer Open
Background: Computed tomography with bone scans (CT-B) has been widely used for staging metastatic hormone-sensitive prostate cancer (mHSPC), but whole-body magnetic resonance imaging (WB-MRI) is increasingly adopted. This study compares W…
View article: 177Lu-PSMA-617 for metastatic prostate cancer in India
177Lu-PSMA-617 for metastatic prostate cancer in India Open
© 2024 The Author(s). Published by Elsevier Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC), https://creativecommons.org/licenses/by-nc…
View article: Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab Open
Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation be…
View article: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study Open
Background Immune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prog…
View article: Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study Open
Background Although nivolumab prolongs overall survival (OS) in pretreated patients with metastatic renal cell carcinoma (mRCC), underlining clinical and biological features of long-term responses are still to be determined. This study aim…
View article: International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study)
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study) Open
Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the Interna…
View article: Prediction of oncogene mutation status in non-small cell lung cancer: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods
Prediction of oncogene mutation status in non-small cell lung cancer: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods Open
Background In non-small cell lung cancer (NSCLC), alternative strategies to determine patient oncogene mutation status are essential to overcome some of the drawbacks associated with current methods. We aimed to review the use of radiomics…
View article: Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” Open
The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine kinase inhibitors (TKIs). The choice among the many differ…
View article: Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study) Open
Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-respo…
View article: Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer Open
Importance Randomized clinical trials (RCTs) with neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non–small cell lung cancer (NSCLC) have reported consistent associations w…
View article: Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer
Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer Open
The management of prostate cancer increasingly relies on androgen axis–targeted therapies, such as enzalutamide, which is now administered progressively earlier and for longer durations ([1][1]). Enzalutamide increases the risk of fatigue,…
View article: Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas Open
Our findings indicate that the differential expression of specific DMD transcripts is associated with poor survival in mesothelioma patients. The specific Dp71 transcript can serve as a potential biomarker for predicting patient survival i…